BUDAPEST, HUNGARY and PRINCETON, NJ and LONDON--(Marketwire - May 12, 2011) -
| Highlighted Links |
|
|
ThalesNano today reported that the China Patent and Trademark Office (CPO) has granted a patent for its flow ozonolysis instrument, the O-Cube™, including several aspects of its proprietary underlying technology.
Ozonolysis is a fundamentally important oxidation reaction, which has never been fully adopted due to the safety concerns with performing the process. The O-Cube™ reinvents the use of ozone in chemical reactions by enabling safe, fast and cost-efficient ozonolysis with superior yields when compared to conventional methods. The O-Cube™'s low temperature capability means the system is also able to perform other types of hazardous reactions in the same compact reactor, dramatically increasing its potential utility.
Dr. Laszlo Urge, CEO of ThalesNano, said: “We are delighted that the CPO has granted us full patent approval for the O-Cube™. Since launching our first instrument, the H-Cube®, in 2004, this is the second time that China, a market leading country, has recognized the importance of patenting such a disruptive technology.”
Richard Jones, Head of R&D and Product Management, added: “Our technology is utilized successfully in 32 countries worldwide and has made a dramatic impact in increasing the level of safety of hazardous processes allowing chemists to tap into previously forbidden chemistries. China is a country of enormous potential for us and this patent will give us the confidence to fully implement this technology into the region, helping Chinese chemists to gain the same benefits that chemists in other countries have already been exploiting. We will continue to pursue patent protection for the O-Cube™ in other geographies.”
About ThalesNano Inc.
ThalesNano is the world leader in bench-top flow chemistry reactors. The company has the widest portfolio of continuous process instruments for the pharmaceutical, biotech, fine chemical, petroleum/biofuel, and education markets. Its R&D 100 award winning H-Cube® and scale-up system H-Cube Midi™ are used in hundreds of laboratories globally and have become the new industry standard for hydrogenation. Within three years from the original introduction of its flagship H-Cube® product, 20 out of the top 20 pharmaceutical companies have introduced and adopted the technology.
Contact:
Dr. Laszlo Urge
Email Contact
